5-MeO-NET, also known as 5-methoxy-N-ethyltryptamine, is a serotonin receptor agonist and serotonin releasing agent of the tryptamine family.
5-MeO-NET was not included nor mentioned in Alexander Shulgin's book TiHKAL (Tryptamines I Have Known and Loved).
5-MeO-NET is a potent full agonist or near-full agonist of the serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> receptors. The drug is a relatively weak serotonin releasing agent.
It does not produce the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents, suggesting that it would not be hallucinogenic in humans. However, 5-MeO-NET does produce the HTR if it is coadministered with a serotonin 5-HT<sub>1A</sub> receptor antagonist like WAY-100635, suggesting that its serotonin 5-HT<sub>1A</sub> receptor agonism masks or blocks its own serotonin 5-HT<sub>2A</sub> receptor-mediated HTR induction.
5-MeO-NET, chemically known as 5-methoxy-N-ethyltryptamine, is a synthetic substituted tryptamine and a N-Ethyltryptamine derivative.
Analogues of 5-MeO-NET include N-Ethyltryptamine (NET), 4-HO-NET, 4-AcO-NET, ñET, 4-HO-ñET, 5-MeO-ñET, 5-chloro-ñMT (PAL-542), 5-fluoro-ñET (PAL-545), 5-MeO-MET, 5-MeO-DMT, 5-MeO-DET, 5-MeO-MPT, 5-MeO-EPT, 5-MeO-MALT, and 5-MeO-MiPT, among others.
5-MeO-NET was first described in the scientific literature by at least 1994. Research on 5-MeO-NET since the early 2000s has primarily focused on its interactions with serotonin receptors and other targets, as well as behavioral effects in rodent models.